MEDIPOST Completes Phase 2a Clinical Trial of NEUROSTEM for Alzheimer’s Disease2020/07/07STEM CELL THERAPEUTIC
MEDIPOST Completes Phase 2a Clinical Trial of NEUROSTEM for Alzheimer’s Disease2020/01/06STEM CELL THERAPEUTIC
MEDIPOST’s Alzheimer’s Disease Drug Approved by FDA for Clinical Trials2018/02/05STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent for Core Alzheimer’s Disease Treatment Technology in Six European Countries2017/10/25STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in Canada for its Stem Cell-based Alzheimer’s Disease Treatment Composition2017/06/28STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in UK for its Alzheimer’s Disease Treatment Technique that Uses Stem Cells2017/05/17STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in US for its Alzheimer’s Disease Treatment Drug2016/06/08STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in China for its Alzheimer’s Disease Treatment Substance2016/04/06STEM CELL THERAPEUTIC
MEDIPOST Obtains Stem Cell Therapy Patent in Japan for Treating Alzheimer’s Disease2016/01/13STEM CELL THERAPEUTIC
Core dementia treatment technology patented at 6 European countries, concurrently2015/07/30STEM CELL THERAPEUTIC
Successful administration of stem cell dementia treatment drug ‘NEUROSTEM’2014/04/28STEM CELL THERAPEUTIC